ClinicalTrials.gg
Not yet recruitingNCT07665866OBCUpdated Jun 24, 2026

Suivi Prospectif Des ostéomyélites de la Base du crâne

An observational study in Malignant External Otitis (Necrotizing/Malignant Otitis Externa) and Central Skull Base Osteomyelitis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, 1 of them phase 3. Communicable Diseases · Assistance Publique - Hôpitaux de Paris.

Started
2026
the only one that year
Observational
8 of 10
4 open now
Registered
10th of 10
by date

Among the 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is one of 8 observational ones, and was the 10th registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

5 of the 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Communicable Diseases by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Skull base osteomyelitis (SBO) is a rare and complex infection that includes malignant external otitis and central skull base osteomyelitis.

Symptoms are often non-specific, and the disease typically progresses slowly, leading to delays in diagnosis and treatment, as well as local or regional complications.

Management is not standardized and consists of medical treatment tailored to microbiological sampling results (antibiotic or antifungal therapy). Monitoring strategies and treatment modalities, particularly treatment duration, have not been standardized.

Given the rarity of these infections, it is currently very difficult to conduct prospective studies comparing different management approaches.

Read the detailed description

This will be a prospective multicenter study involving departments of Otorhinolaryngology (ENT), Infectious Diseases, Diabetology, and Internal Medicine.

Patients receiving care for skull base osteomyelitis who are seen either in outpatient consultation or during hospitalization will be included in the study, provided that their non-objection to participation has been obtained.

Patients will be managed and monitored according to standard clinical practice (routine care).

03

Conditions studied

  • Malignant External Otitis (Necrotizing/Malignant Otitis Externa)
  • Central Skull Base Osteomyelitis

Browse trials for

Keywords

  • Skull Base Osteomyelitis (SBO)
  • Osteomyelitis of the Skull Base
  • Malignant External Otitis
  • Skull Base Infection
  • Infectious Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients aged 18 years or older diagnosed with skull base osteomyelitis (see definition below) during outpatient consultation or hospitalization at Lariboisière Hospital will be eligible for inclusion in the study, provided that they do not object to participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria:
  • Age ≥ 18 years.
  • Diagnosis of skull base osteomyelitis, based on the combination of:
  • Clinical signs: otorrhea and/or otalgia and/or granulation tissue in the external -auditory canal, headache(s) and/or paralysis of one or more cranial nerves;
  • AND radiological findings: bone destruction/osteolysis demonstrated on CT scan and/or MRI.

Exclusion criteria

Exclusion Criteria:

  • Participants meeting any of the following criteria will be excluded:

Expressed refusal (objection) to participate in the study. Individuals under legal protection measures (guardianship, curatorship, or judicial protection).

Patients managed for osteoradionecrosis. Patients managed for squamous cell carcinoma of the external auditory canal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
36 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. One-year prognosis of skull base osteomyelitis

    assessed by the occurrence of recurrence, relapse, and all-cause mortality within 12 months after diagnosis. Time Frame: 12 months.

    Time frame: 1 year

07

Study locations

1 site
  • Lariboisière Hospital, 2 rue Ambroise Paré
    Paris, 75010, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2029, 35 months later.

Of 128 non-industry observational studies under Communicable Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's planned 35 months is close to that.

Counting every sponsor, half of 142 studies reached it within 37 months; a quarter within 17 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 24, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07665866
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Jun 24, 2026

Study contacts

Munier Anne-Lise, PH
Contact
anne-lise.munier@aphp.fr
0149956339

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion